Your basket is currently empty!
Pexa-Vec with immunotherapy reduced tumor in 75% of RCC patients
San Francisco based SillaJen Biotherapeutics said a combination of its oncolytic viral therapy Pexa-Vec (JX-594) ...
News Archive
Pexa-Vec
Our work depends on donations from generous people so that we can support those affected by kidney cancer.
Would you like to support our work through a donation?
